The Beijing Angle Closure Progression Study
Recruiting · NCT05563623 · Observational (researchers observe without assigning treatment) · Lead sponsor: Peking University People's Hospital
View the official record on ClinicalTrials.gov →What this trial is about
The Beijing angle closure progression study (BAPS) aims to explore the 5-year incidence of PACS progressing to PAC or PACG and to determine the possible risk factors of disease progression, which may provide the evidence for choosing the accurate strategies in the management of PACS.
Who can take part
Age range
40 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- "Static" gonioscopy identifying 6 or more clock hours of angle circumference in which the posterior (usually pigmented) trabecular meshwork cannot be seen in both eyes with no peripheral anterior synechiae, and normal intraocular pressure (IOP), optic nerve and visual field.
- Able to provide informed consent
Exclusion criteria
- Any evidence of primary angle closure (a narrow angle as defined above, but with PAS and/or IOP \> 21 mmHg) or primary angle closure glaucoma (visual field defect or glaucomatous optic neuropathy).
- Previous intraocular surgery or laser treatment, such as cataract surgery, laser trabeculoplasty, trabeculectomy, laser peripheral iridectomy, and laser iridoplasty
- Sign of prior acute attack, such as glaucomatous fleck, keratic precipitates, or iris atrophy.
- Anterior segment structural abnormalities shown by examination, such as iris or ciliary body tumor.
- Severe health problems precluding follow-up such as end-stage heart disease, kidney disease, or lung disease, or terminal cancer.
- Severe eye diseases, such as cataract, macular disease, and retinal detachment.
Where it is running
1 location listed.
- Peking University People's Hospital - Beijing, Beeijing, China